Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

N/A

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02934620Not ApplicableCompleted

Promoting CSD500 Use Among Women in Established Relationships

Role: collaborator

NCT03590691Not ApplicableCompleted

Conquering Hypertension in Vietnam: Solutions at Grassroots Level

Role: lead

NCT04328493Phase 2Completed

The Vietnam Chloroquine Treatment on COVID-19

Role: collaborator

NCT03204227Phase 2Completed

Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age

Role: collaborator

NCT03282370Phase 3Completed

Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam

Role: collaborator

NCT02816554Phase 2Completed

Safety and Immunogenicity of JECEVAX in Young Children

Role: collaborator

All 6 trials loaded